Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody

• Published in: International journal of hematology Vol. 115; no. 1; pp. 7 - 10
• Main Authors: Funakoshi, Yohei, Yakushijin, Kimikazu, Ohji, Goh, Hojo, Wataru, Sakai, Hironori, Watanabe, Marika, Saeki, Miki, Hirakawa, Yuri, Sakai, Rina, Matsumoto, Sakuya, Mizutani, Yu, Kitao, Akihito, Miyata, Yoshiharu, Saito, Yasuyuki, Kawamoto, Shinichiro, Yamamoto, Katsuya, Ito, Mitsuhiro, Nishimura, Meiko, Imamura, Yoshinori, Kiyota, Naomi, Matsuoka, Hiroshi, Mori, Yasuko, Minami, Hironobu
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 2022; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Antibodies; Antibodies, Monoclonal, Humanized - therapeutic use; Antibody Formation; Antigens, CD20 - immunology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; BNT162 Vaccine - therapeutic use; CD20 antigen; Coronaviruses; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 vaccines; Cyclophosphamide - therapeutic use; Doxorubicin - therapeutic use; Female; Hematology; Humans; Immune response (cell-mediated); Immunization; Lymphocytes B; Lymphocytes T; Lymphoma, B-Cell - complications; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - immunology; Male; Medicine; Medicine & Public Health; Middle Aged; mRNA; Oncology; Patients; Prednisone - therapeutic use; Rapid Communication; Rituximab - therapeutic use; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines; Vincristine - therapeutic use; SARS-CoV-2 vaccination; Anti-CD20 antibody; B-cell malignancies
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-021-03247-y

We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.